Welcome
Dear Collegues, dear Friends,
Welcome to the 4th European Expert Meeting on Rotavirus Vaccination! Join your colleagues to discuss and, hopefully, promote, rotavirus vaccination in Europe. Since the first, second and third European Expert meetings on Rotavirus vaccination in Helsinki (2009), Padova (2011) and Leipizig (2013) our knowledge and experience on rotavirus vaccination has expanded considerably.
Rotavirus is still the main cause of severe acute diarrhoea in infancy and early childhood around the world. It is still associated with high mortality in poorer countries. Before licensure two rotavirus vaccines were tested worldwide for safety, immunogenicity and efficacy in 2 trials comprising over 60 000 infants each. One of these is a single-strain attenuated human rotavirus vaccine (RV1), while the other is a combination of five bovine–human reassortant rotaviruses (RV5). Although their presumed mechanism of action might be very different side effects and effectiveness are close to identical. Both vaccines prevent severe rotavirus gastroenteritis (RVGE), but are less efficacious against mild RVGE or rotavirus infection. Field effectiveness of these vaccines in Singapure, Europe and the USA against severe RVGE has been above 90%, whereas in Africa it is only around 60%.
The phenomenon of reduced rotavirus vaccine efficacy may be predicted by intrinsic immunological and epidemiological factors of low socio-economic settings.
See you in Santiago!

Federico Martinón-Torres
